The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
BACKGROUND: Etrasimod is an investigational, oral, once-daily (QD), selective sphingosine 1-phosphate (S1P)1,4,5 receptor modulator in development to treat immune-mediated inflammatory disorders…
The goals of treatment of eosinophilic esophagitis (EoE) are to improve clinical symptoms and histologic features, as well as prevent progression to fibrostenotic complications. Few data currently exist that evaluate the effectiveness of therapies as measured by complete resolution of symptoms…